TRCT
CLOV icon

Tower Research Capital (TRC)’s Clover Health Investments CLOV Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLOV Stock Details CLOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
30,555
+413
+1% +$1.4K ﹤0.01% 1858
2026
Q1 		$53K Buy
30,142
+12,632
+72% +$27.4K ﹤0.01% 2694
2025
Q4 		$41.1K Buy
17,510
+1,184
+7% +$3.24K ﹤0.01% 2575
2025
Q3 		$50K Sell
16,326
-6,590
-29% -$18.8K ﹤0.01% 2529
2025
Q2 		$63.9K Buy
22,916
+14,730
+180% +$48.4K ﹤0.01% 2758
2025
Q1 		$29.4K Sell
8,186
-37,900
-82% -$152K ﹤0.01% 2631
2024
Q4 		$145K Buy
46,086
+44,533
+2,868% +$159K ﹤0.01% 1922
2024
Q3 		$4.38K Sell
1,553
-40,167
-96% -$91.9K ﹤0.01% 4565
2024
Q2 		$51.3K Buy
41,720
+34,065
+445% +$30.6K ﹤0.01% 3080
2024
Q1 		$6.08K Sell
7,655
-1,040
-12% -$946 ﹤0.01% 4438
2023
Q4 		$8.28K Sell
8,695
-12,354
-59% -$12.1K ﹤0.01% 4525
2023
Q3 		$22.7K Sell
21,049
-3,594
-15% -$4.28K ﹤0.01% 3261
2023
Q2 		$22.1K Sell
24,643
-2,247
-8% -$1.99K ﹤0.01% 3299
2023
Q1 		$23K Buy
26,890
+13,393
+99% +$14.7K ﹤0.01% 3276
2022
Q4 		$13K Sell
13,497
-29,372
-69% -$39.2K ﹤0.01% 3586
2022
Q3 		$73K Sell
42,869
-67,686
-61% -$177K ﹤0.01% 2837
2022
Q2 		$237K Buy
110,555
+85,915
+349% +$228K 0.01% 1643
2022
Q1 		$87K Buy
24,640
+24,220
+5,767% +$70.2K ﹤0.01% 2311
2021
Q4 		$2K Sell
420
-2,889
-87% -$17.7K ﹤0.01% 5607
2021
Q3 		$24K Sell
3,309
-6,810
-67% -$58.3K ﹤0.01% 3552
2021
Q2 		$135K Sell
10,119
-77
-0.8% -$756 ﹤0.01% 2185
2021
Q1 		$77K Buy
10,196
+6,767
+197% +$76.4K ﹤0.01% 2787
2020
Q4 		$58K Buy
3,429
+2,429
+243% +$27K ﹤0.01% 2949
2020
Q3 		$12K Buy
+1,000
New +$11.1K ﹤0.01% 4017

Other funds holding CLOV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Tower Research Capital (TRC)'s CLOV Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Clover Health Investments (CLOV) stake by 1.4% in Q2 2026, buying an estimated $1.4K and bringing the position to 30,555 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Tower Research Capital (TRC) first reported a position in CLOV in Q3 2020 and has held it in 24 quarters since. The position peaked at $237K in Q2 2022. 226 funds tracked by Wall St. Rank hold CLOV as of Q2 2026.

  • Tower Research Capital (TRC) held 30,555 shares of Clover Health Investments worth $160K as of Q2 2026.
  • Tower Research Capital (TRC) bought 413 Clover Health Investments shares in Q2 2026, an estimated $1.4K.
  • Clover Health Investments made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1858 holding.
  • Tower Research Capital (TRC) first reported a position in Clover Health Investments in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Clover Health Investments position peaked at $237K in Q2 2022.
  • 226 funds tracked by Wall St. Rank held Clover Health Investments as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.